Immune Checkpoint Inhibitor-Mediated Cardiovascular Disease: The Dark Side of the Monoclonal Anti-Body Therapy against Cancer

Endocr Metab Immune Disord Drug Targets. 2023;23(11):1365-1367. doi: 10.2174/1871530323666230416153426.

Authors

Carlo Caiati¹, Emilio Jirillo¹

Affiliation

¹ Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.

PMID: 37062060
DOI: 10.2174/1871530323666230416153426

No abstract available

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Cardiovascular Diseases* / chemically induced
Cardiovascular Diseases* / drug therapy
Humans
Immune Checkpoint Inhibitors / adverse effects
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological